Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + pelareorep
- Development stage
- Unknown
- Lead developer
- Oncolytics Biotech
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Docetaxel + pelareorep is a combination therapy under investigation for the treatment of various cancers, notably metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors. Docetaxel is a taxane-class small molecule chemotherapeutic agent that promotes microtubule assembly and stabilizes them against depolymerization, thereby inhibiting cell division and inducing apoptosis in rapidly dividing cancer cells[1][3]. Pelareorep is an oncolytic virus (a proprietary isolate of reovirus type 3 Dearing strain) that selectively infects and replicates within cancer cells, leading to direct tumor cell lysis. Additionally, pelareorep induces an inflammatory response in the tumor microenvironment, upregulates PD-L1 expression, enhances T-cell infiltration, and can convert immunologically "cold" tumors into "hot" ones to improve immune recognition[6]. The combination has been evaluated in clinical trials for synergistic effects due to their complementary mechanisms—docetaxel’s cytotoxicity with pelareorep’s immunomodulatory oncolytic activity[2].
- Brand names
- REOLYSIN + Taxotere
- Other names
- Oncolytics ReovirusREOLYSIN
02
Targets
BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))JAM-A (Junctional adhesion molecule A)
Beyond the preview
Go deeper on docetaxel + pelareorep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + pelareorep.